WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Pharma Line srl
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Prnewswire | August 18, 2020
Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...
BUSINESS INSIGHTS
AIkido Pharma Inc. | May 05, 2022
AIkido Pharma Inc. announced that the Company has secured an early equity interest in privately-held Discord, Inc. a social communications platform provider that is particularly popular with gamers. Bloomberg Technology reported on March 14, 2022, that Discord "is interviewing bankers about going public as soon as this year." According to the Bloomberg report, "Discord, last valued by private investors at about $15 billion, is especially popular with gamers and youn...
CPD AND LEARNING
PostEra | November 27, 2020
PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel littl...
AbCellera | May 04, 2022
AbCellera and Empirico Inc. announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights PlatformTM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets. Following the rapid progress of their first collaborative program, which identified a lead candidate against an undisclosed G protein-coupled receptor target in less than 12 ...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE